Technical Analysis for KZIA - Kazia Therapeutics Limited - American Depositary Shares

Grade Last Price % Change Price Change
grade C 2.91 9.81% 0.26
KZIA closed up 9.81 percent on Tuesday, September 17, 2019, on 3.11 times normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Flat Up Up
See historical KZIA trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Shooting Star Candlestick Bearish 9.81%
Lizard Bearish Bearish Day Trade Setup 9.81%
Calm After Storm Range Contraction 9.81%
Doji - Bearish? Reversal 9.81%

Older signals for KZIA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
Biotechnology Cancer Organ Systems ATM Chemotherapy Ovarian Cancer Neuroblastoma Glioma Pharmaceutical Research Diffuse Intrinsic Pontine Glioma
Is KZIA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.27
52 Week Low 2.04
Average Volume 1,896
200-Day Moving Average 2.9173
50-Day Moving Average 2.5786
20-Day Moving Average 2.4854
10-Day Moving Average 2.5813
Average True Range 0.1463
ADX 14.95
+DI 38.8694
-DI 22.4321
Chandelier Exit (Long, 3 ATRs ) 2.5011
Chandelier Exit (Short, 3 ATRs ) 2.7048
Upper Bollinger Band 2.7985
Lower Bollinger Band 2.1723
Percent B (%b) 1.18
BandWidth 25.19514
MACD Line 0.0432
MACD Signal Line -0.0114
MACD Histogram 0.0545
Fundamentals Value
Market Cap 14.06 Million
Num Shares 4.83 Million
EPS -1.80
Price-to-Earnings (P/E) Ratio -1.62
Price-to-Sales 2.05
Price-to-Book 0.71
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.11
Resistance 3 (R3) 3.09 3.02 3.07
Resistance 2 (R2) 3.02 2.97 3.02 3.06
Resistance 1 (R1) 2.96 2.94 2.99 2.98 3.05
Pivot Point 2.89 2.89 2.90 2.89 2.89
Support 1 (S1) 2.83 2.84 2.86 2.85 2.77
Support 2 (S2) 2.76 2.81 2.76 2.76
Support 3 (S3) 2.70 2.76 2.75
Support 4 (S4) 2.72